A trial of contraceptive methods in women with systemic lupus erythematosus

New England Journal of Medicine

Volumn 353, Issue 24, 2005, Pages 2539-2549

  Sánchez Guerrero, Jorge ^a   Uribe, América G ^a   Jiménez Santana, Luisa ^a   Mestanza Peralta, Marilú ^a   Lara Reyes, Pilar ^a   Seuc, Armando H ^b   Cravioto, María Del Carmen ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; LEVONORGESTREL; NORDET; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTERY THROMBOSIS; ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; INFECTION; INTRAUTERINE CONTRACEPTIVE DEVICE; LEG THROMBOSIS; MAJOR CLINICAL STUDY; MENINGITIS; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ADULT; CONTRACEPTIVES, ORAL; ETHINYL ESTRADIOL; FEMALE; HUMANS; INTRAUTERINE DEVICES; LEVONORGESTREL; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 28944431771     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa050817     Document Type: Article

References (40)

1. Alarcon-Segovia D. The pathogenesis of immune dysregulation in systemic lupus erythematosus: a troika. J Rheumatol 1984;11:588-90.
2. Systemic lupus erythematosus. In: Silman AJ, Hochberg MC, eds. Epidemiology of the rheumatic diseases. New York: Oxford University Press, 1993:163-91.
3. Sánchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk of developing systemic lupus erythematosus. Ann Intern Med 1995;122:430-3.
4. Sánchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997;40:804-8.
5. Rose E, Pillsbury DM. Lupus erythematosus and ovarian function: observations on a possible relationship with a report of 6 cases. Ann Intern Med 1944;21:1022-34.
6. Mund A, Simson J, Rothfield N. Effect of pregnancy on course of systemic lupus erythematosus. JAMA 1963;183:917-20.
7. Barrett C, Neylon N, Snaith ML. Oestrogen-induced systemic lupus erythematosus. Br J Rheumatol 1986;25:300-1.
8. Sánchez-Guerrero J, Villegas A, Mendoza-Fuentes A, Romero-Díaz J, Moreno-Coutiño G, Cravioto MC. Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus. Am J Med 2001;111:464-8.
9. Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 1999;42:1274-80.
10. Kelley VE, Winkelstein A. Age- and sex-related glomerulonephritis in New Zealand white mice. Clin Immunol Immunopathol 1980;16:142-50.
11. Roubinian JR, Talal N, Greenspan JS, Goodman JR, Siiteri PK. Delayed androgen treatment prolongs survival in murine lupus. J Clin Invest 1979;63:902-11.
12. Idem. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/ NZW F1 mice. J Exp Med 1978;147:1568-83.
13. Bynoe MS, Grimaldi CM, Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naïve B cells. Proc Natl Acad Sci U S A 2000;97:2703-8.
14. Clowse MEB, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21.
15. Ramsey-Goldman R. Pregnancy in systemic lupus erythematosus. Rheum Dis Clin North Am 1988;14:169-85.
16. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization, 2004. (Accessed November 17, 2005, at http://www.who.int/ reproductive-health/publications.)
17. Farley TM, Rosenberg MS, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-8.
18. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.
19. Mintz G, Gutierrez G, Deleze M, Rodriguez E. Contraception with progestagens in systemic lupus erythematosus. Contraception 1984;30:29-38.
20. Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982;25:618-23.
21. Garovich M, Agudelo C, Pisko E. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1980;23:1396-8.
22. Chapel TA, Burns RE. Oral contraceptives and exacerbation of lupus erythematosus. Am J Obstet Gynecol 1971;110:366-9.
23. Gill D. Rheumatic complaints of women using anti-ovulatory drugs: an evaluation. J Chronic Dis 1968;21:435-44.
24. DuBois EL, Strain L, Ehn M, Bernstein G, Friou GJ. L.E. cells after oral contraceptives. Lancet 1968;2:679.
25. Tarzy BJ, Garcia CR, Wallach EE, Zweiman B, Myers AR. Rheumatic disease, abnormal serology, and oral contraceptives. Lancet 1972;2:501-3.
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
27. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
28. Gladman DD, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
29. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus: a prospective cohort study. Arthritis Rheum 1991;34:937-44.
30. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
31. Travers RL, Hughes GR. Oral contraceptive therapy and systemic lupus erythematosus. J Rheumatol 1978;5:448-51.
32. Buyon J, Kalunian K, Skovron ML, et al. Can women with systemic lupus erythematosus safely use exogenous estrogens? J Clin Rheumatol 1995;1:205-12.
33. Kreidstein S, Urowitz MB, Gladman DD, Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol 1997;24:2149-52.
34. Petri M, Buyon JP, Kim M, et al. Combined oral contraceptives are not associated with an increased rate of flare in SLE patients in SELENA. Arthritis Rheum 2004;50:S239.
35. Parkar M, Tabona P, Newman H, Olsen I. IL-6 expression by oral fibroblasts is regulated by androgen. Cytokine 1998;10:613-9.
36. Siiteri PK, Febres F, Clemens LE, Chang RJ, Gondos B, Stites D. Progesterone and maintenance of pregnancy: is progesterone nature's immunosuppressant? Ann N Y Acad Sci 1977;286:384-97.
37. Bland JM, Altman DG. Regression towards the mean. BMJ 1994;308:1499.
38. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002;29:2531-6.
39. Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004;164:1965-76.
40. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000;27:377-9.